. 2023 Aug 10;9(10):1457–1459. doi: 10.1001/jamaoncol.2023.2789

Table. Summary of Survival in the 5-Year Final Analysis.

	No. of events (%)		KM estimate, mo		Treatment difference KM estimate, % (80% CI)^c	Overall unstratified HR (80% CI)^d
	Group 1 (n = 76)^a	Group 2 (n = 74)^b	Group 1^a	Group 2^b	Treatment difference KM estimate, % (80% CI)^c	Overall unstratified HR (80% CI)^d
LRFS	53 (69.7)	56 (75.7)	28.02	21.12	6.90 (−2.60 to 16.40)	0.82 (0.64 to 1.06)
RRFS	50 (65.8)	54 (73.0)	32.91	24.69	8.22 (−1.58 to 18.01)	0.81 (0.62 to 1.05)
DMFS	54 (71.1)	61 (82.4)	27.62	14.99	12.63 (3.79 to 21.48)	0.73 (0.57 to 0.94)

Abbreviations: DMFS, distant metastasis–free survival; HR, hazard ratio; KM, Kaplan-Meier; LRFS, local recurrence-free survival; RRFS, regional recurrence-free survival.

^{^a}

Talimogene laherparepvec plus surgery.

^{^b}

Surgery alone.

^{^c}

Group 1 – group 2.

^{^d}

Group 1 / group 2.